Antibodies to endogenous and recombinant erythropoietin

  • Patrick Mayeux
  • Nicole Casadevall
Part of the Milestones in Drug Therapy MDT book series (MDT)


rHuEPO Treatment Uman Serum 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Piercy R, Swardson C, Hinchcliff K (1998) Erythroid hypoplasia and anemia following administration of recombinant human erythropoietin to two horses. J Am Vet Med Assoc 212: 244–247PubMedGoogle Scholar
  2. 2.
    Coscarella A, Liddi R, Di LM, Bach S, Faiella A, van der Meide PH, Mele A, De Santis R (1998) The rhGM-CSF-EPO hybrid protein MEN 11300 induces anti-EPO antibodies and severe anaemia in rhesus monkeys. Cytokine 10: 964–969CrossRefPubMedGoogle Scholar
  3. 3.
    Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I et al. (2002) Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346: 469–475CrossRefPubMedGoogle Scholar
  4. 4.
    Sytkowski A, Feldman L, Zurbuch D (1991) Biological activity and structural stability of N-deglycosylated recombinant human erythropoietin. Biochem Biophys Res Commun 176: 698–704CrossRefPubMedGoogle Scholar
  5. 5.
    Delorme E, Lorenzini T, Giffin J, Martin F, Jacobsen F, Boone T, Elliott S (1992) Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31: 9871–9876CrossRefPubMedGoogle Scholar
  6. 6.
    Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J et al. (1998) Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395: 511–516CrossRefPubMedGoogle Scholar
  7. 7.
    Skibeli V, Nissen-Lie G, Torjesen P (2001) Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 98: 3626–3634CrossRefPubMedGoogle Scholar
  8. 8.
    Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P (1996) Auto-antibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 334: 630–633CrossRefPubMedGoogle Scholar
  9. 9.
    Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, Moroi M, Okada M, Sato Y, Wada H, Yawata Y (1991) Establishment and characterization of a human leukemic cell line with megakaryocytic features: Dependency on granulocyte-macrophage colony stimulating factor, interleukin 3, or erythropoietin for growth and survival. Cancer Res 51: 341–348PubMedGoogle Scholar
  10. 10.
    Castelli G, Famularo A, Semino C, Machi A, Ceci A, Cannella G, Melioli G (2000) Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 41: 313–318CrossRefPubMedGoogle Scholar
  11. 11.
    Urra JM, de la Torre M, Alcazar R, Peces R (1997) Rapid method for detection of anti-recombinant human erythropoietin antibodies as a new form of erythropoietin resistance. Clin Chem 43: 848–849PubMedGoogle Scholar
  12. 12.
    Prabhakar S, Muhlfelder T (1997) Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 47: 331–335PubMedGoogle Scholar
  13. 13.
    Linardaki GD, Boki KA, Fertakis A, Tzioufas AG (1999) Pure red cell aplasia as presentation of systemic lupus erythematosus: Antibodies to erythropoietin. Scand. J Rheumatol 28: 189–191PubMedGoogle Scholar
  14. 14.
    Peschle C, Marmont AM, Marone G, Genovese A, Sasso GF, Condorelli M (1975) Pure red cell aplasia: Studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 30: 411–417PubMedGoogle Scholar
  15. 15.
    Marmont A, Peschle C, Sanguineti M, Condorelli M (1975) Pure red cell aplasia (PRCA): Response of three patients of cyclophosphamide and/or antilymphocyte globulin (ALG) and demonstration of two types of serum IgG inhibitors to erythropoiesis. Blood 45: 247–261PubMedGoogle Scholar
  16. 16.
    Bergrem H, Danielson BG, Eckardt KU, Kurtz A, Strisberg M (1993) A case of anti-erythropoietin antibodies following recombinant human erythropoietin treatment. In: C Bauer, KM Koch, P Scigalla, L Wieczorek (eds): Erythropietin: Molecular physiology and clinical application. Marcel Dekker, New-York, 266–275Google Scholar
  17. 17.
    Peces R, de la Torre M, Alcazar R, Urra JM (1996) Antibodies against recombinant human erythropoietin in a patient with erythropoietin-resistant anemia. N Engl J Med 335: 523–524CrossRefPubMedGoogle Scholar
  18. 18.
    Pazur JH, Jensen PJ, Murray AK (2000) Oligosaccharides as immunodeterminants of erythropoietin for two sets of anti-carbohydrate antibodies. J Protein Chem 19: 631–635PubMedGoogle Scholar
  19. 19.
    Gershon SK, Luksenburg H, Cote TR, Braun MM (2002) Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 346: 1584–1586CrossRefPubMedGoogle Scholar
  20. 20.
    Voulgari PV, Hatzimichael EC, Tsiara S, Tzallas C, Drosos AA, Bourantas KL (2001) Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes. Eur J Haematol 66: 31–36CrossRefPubMedGoogle Scholar

Copyright information

© Birkhüser Verlag/Switzerland 2003

Authors and Affiliations

  • Patrick Mayeux
    • 1
  • Nicole Casadevall
    • 2
  1. 1.Institut Cochin, Département d’Hématologie, INSERM U567Université René Descartes, Hôpital CochinParisFrance
  2. 2.Service d’Hématologie Biologique, INSERM U362Hôpital de l’Hôtel-DieuParis cedex 4France

Personalised recommendations